# Nouscom funding rounds and investors

As of 28 Oct 2026, Nouscom has raised $133.8M across 1 verified round on record (amounts in other currencies converted to USD), plus 3 rounds still being checked; latest: €120 million ($135 million) Series D led by M Ventures and Revelation Partners, announced 19 Oct 2026.

Nouscom is a biotech company selling cancer-preventing vaccine candidates primarily to healthcare providers and clinical trial organizations.

Website: https://group.intesasanpaolo.com/  
Headquarters: Basel, Switzerland  
Page: https://fireround.dev/companies/intesasanpaolo.com

## Verified rounds

| Announced | Round | Amount | Lead investors | Other investors | Sources |
| --- | --- | --- | --- | --- | --- |
| 2026-10-19 | Series D | €120 million ($135 million) | M Ventures, Revelation Partners | Angelini Industries, Neva SGR (Intesa Sanpaolo Bank), 5AM Ventures, Andera Partners, Bpifrance, CDP Venture Capital, EQT Life Sciences, Indaco Venture Partners, Panakes Partners, Versant Ventures, XGEN Venture | [group.intesasanpaolo.com](https://group.intesasanpaolo.com/en/newsroom/all-news/news/2026/venture-capital-neva-sgr-invests-in-nouscom), [eu-startups.com](https://www.eu-startups.com/2026/10/switzerlands-nouscom-bags-e120-million-to-bring-innovative-cancer-immunotherapy-closer-to-clinical-trials), [fiercebiotech.com](https://www.fiercebiotech.com/biotech/nouscom-raises-135m-pivotal-trial-cancer-preventing-vaccine-candidate) |

Source: Fireround (https://fireround.dev), an open-source funding feed. Each round is checked against the pages listed with it.